Search

Your search keyword '"G. Bodini"' showing total 9 results
Start Over Author "G. Bodini" Topic hepatology
9 results on '"G. Bodini"'

1. OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY

Author

F.S. Macaluso, M. Principi, F. Facciotti, A. Contaldo, A. Todeschini, S. Saibeni, C. Bezzio, F. Castiglione, O. Nardone, R. Spagnuolo, M. Fantini, G. Riguccio, F. Conforti, F. Caprioli, C. Vigano, C. Felice, G. Fiorino, C. Correale, G. Bodini, M. Milla, G. Scardino, M. Vernero, F. Desideri, F. Bossa, M. Guerra, M. Ventimiglia, M. Mannino, G. Rizzo, and A. Orlando

Subjects
Hepatology, Gastroenterology
Published
2023

2. T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN’S DISEASE PATIENTS FAILURE TO TNF INHIBITORS

Author

S. Onali, D. Pugliese, F.A. Caprioli, A. Orlando, L. Biancone, O.M. Nardone, N. Imperatore, G. Fiorino, M. Cappello, A. Viola, M.B. Principi, C. Bezzio, A. Aratari, S. Carparelli, F. Mancuso, L. Grossi, G. Bodini, D. Ribaldone, G. Mocci, A. Favale, M. Grova, L. Scucchi, S. Segato, W. Fries, F. Castiglione, A. Armuzzi, and M.C. Fantini

Subjects
Hepatology, Gastroenterology
Published
2022

3. PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IG-IBD STUDY

Author

F.S. Macaluso, M. Principi, F. Facciotti, A. Contaldo, A. Todeschini, S. Saibeni, C. Bezzio, F. Castiglione, O.M. Nardone, R. Spagnuolo, P. Doldo, M.C. Fantini, S. Paba, G. Riguccio, F.S. Conforti, C. Viganò, M. Ascolani, G. Bodini, M. Milla, G. Scardina, M. Vernero, F. Desideri, M. Mannino, G. Rizzo, F.A. Caprioli, and A. Orlando

Subjects
Hepatology, Gastroenterology
Published
2022

6. OC.12.6 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1

Author

G. Bergamaschi, M.V. Lenti, P. Giuffrida, S. Soriano, R. D'Incà, M. Astegiano, N. Aronico, W. Fries, F. Rizzello, C. Ciacci, F. Bossa, A. Orlando, G. Ghigliazza, F. Castiglione, M. Milla, S. Nardelli, M.B. Principi, M.L. Scribano, C. Ricci, D. Mazzucco, G. Riegler, G. Bassotti, A. Buda, M. Neri, G. Bodini, F. Monica, A. Manca, E. Villa, M. Comberlato, S. Saibeni, C. Bezzio, L. Sidoli, R. Cannatelli, V. Neve, P. Vernia, A. Pieraccini, A. Testa, C. Mengoli, G. Rizzuto, R. Fontana, P. Iovino, C. Valerii, T. Pinto Vraca, E. Ponzo, R. Caccaro, G.R. Corazza, and A. Di Sabatino

Subjects
Hepatology, Gastroenterology
Published
2020

8. OC.02.5 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART1

Author

G. Bergamaschi, P. Giuffrida, W. Fries, N. Aronico, R. D'Incà, M.V. Lenti, C. Ciacci, S. Cococcia, F. Bossa, G. Ghigliazza, F. Castiglione, M.B. Principi, C. Ricci, D. Mazzucco, M. Milla, A. Pieraccini, M.L. Scribano, G. Riegler, G. Bodini, G. Bassotti, F. Monica, M. Masotti, P. Vernia, A. Manca, A. Buda, E. Villa, M. Neri, M. Comberlato, A. Testa, S. Soriano, R. Fontana, P. Iovino, G.C. Sturniolo, G.R. Corazza, and A. Di Sabatino

Subjects
Hepatology, Gastroenterology
Published
2018

9. Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma

Author

Giannini, EDOARDO GIOVANNI, Bodini, G., Corbo, M., Savarino, Vincenzo, Risso, Domenico, DI NOLFO, M. A., DEL POGGIO, P., Benvegnù, L., Farinati, F., Zoli, M., Borzio, F., Caturelli, E., Chiaramonte, M., Trevisani, F., ITALIAN LIVER CANCER GROUP, E.G. Giannini, G. Bodini, M. Corbo, D. Risso, V. Savarino, M.A. Di Nolfo, P. Del Poggio, L. Benvegnù, F. Farinati, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, and for the Italian Liver Cancer (ITALI.CA.) group

Subjects
Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, EVIDENCE-BASED MEDICINE, Population, Kaplan-Meier Estimate, Gastroenterology, Internal medicine, medicine, Carcinoma, Humans, Pharmacology (medical), HEPATOCELLULAR CARCINOMA, Chemoembolization, Therapeutic, education, Survival rate, Aged, Randomized Controlled Trials as Topic, Retrospective Studies, education.field_of_study, Hepatology, business.industry, Patient Selection, Liver Neoplasms, Cancer, Retrospective cohort study, TREATMENT, Middle Aged, medicine.disease, Survival Rate, Treatment Outcome, Italy, Hepatocellular carcinoma, Female, Liver cancer, business
Abstract

Aliment Pharmacol Ther 31, 493–501 Summary Background A randomized controlled trial performed by the Barcelona Clinic Liver Cancer (BCLC) published in 2002 demonstrated that transcatheter arterial chemoembolisation (TACE) is an effective treatment for well-selected patients with unresectable hepatocellular carcinoma (HCC). Aim To access whether this information has modified the use of TACE in clinical practice. Methods From 2042 HCC patients included in the Italian Liver Cancer database, we selected 336 cases diagnosed over two 4-year periods (1999–2002, n = 161 and 2003–2006, n = 175), fulfilling the inclusion criteria of the BCLC study. These groups were compared for TACE application rate, patient characteristics and survival. Results Patients undergoing TACE increased in the 2003–2006 period (from 62% to 73%, P = 0.035), with an increase in of Child-Pugh class A (from 64% to 77%, P = 0.048) and advanced HCC patients (from 54% to 69%, P = 0.041). In the 1999–2002 period, there was no significant difference in survival between TACE-treated and untreated patients, while in the 2003–2006 period, TACE-treated patients survived longer (P

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results